Crossmark

SOX combined with intraperitoneal perfusion of docetaxel compared with DOS regimen in the first-line therapy for advanced gastric cancer with malignant ascites: a prospective observation

Crossref DOI link: https://doi.org/10.1186/s13063-022-06143-w

Published Online: 2022-03-12

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bin, Yehong

Lan, Dong

Bao, Wenguang

Yang, Haiyan

Zhou, Shengsheng

Huang, Fengxiang

Wang, Man

Peng, Zhigang https://orcid.org/0000-0001-7408-9237
Funding

Funding for this research was provided by:

the Self-financing project of Guangxi Health Commission of China (Z2016293)
License Information

Text and Data Mining valid from 2022-03-12

Version of Record valid from 2022-03-12
More Information

Article History

Received: 7 May 2021

Accepted: 3 March 2022

First Online: 12 March 2022

Declarations

:

: This study was conducted in accordance with the principles of Helsinki Declaration and Good Clinical Practice and was approved by the Institutional Review Boards of Guangxi Medical University Medical Center. Written informed consents were obtained from all patients.

: Written informed consents were obtained from all patients.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below